Poolbeg Pharma to Participate in Key Conferences in September 2026
Poolbeg Pharma to showcase POLB 001 at leading scientific and investor conferences
3 September 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has been selected to present at a number of leading international conferences this September.
